Unicycive Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Schiller Brigitte, was filed 17 May 2022.
Unicycive Therapeutics, Inc.: what insiders have been doing
We have very little insider data for Unicycive Therapeutics, Inc. so far: the most recent filing dates from 1 July 2026. With so few records, no pattern can be drawn yet. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Since the insiders bought
- +73.7%Entry US$8.00 · Close at T+365 US$13.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Unicycive Therapeutics, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$28.40.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 1,789,916 shares@ US$5.287.33% mcap100.0% of flowCommonSEC144:0001178937-26-000032
- 652,900 sharesCommon StockSEC:0001213900-25-080808:0
- 1,400,000 sharesCommon StockSEC:0001213900-25-015152:0
- 5,500,000 sharesCommon StockSEC:0001213900-24-086928:0
- 3,470,152 sharesCommon StockSEC:0001213900-23-056885:0
- 104,612 sharesCommon StockSEC:0001213900-23-056875:0
- 104,612 sharesCommon StockSEC:0001213900-23-056848:0
- 41,845 sharesCommon StockSEC:0001213900-23-056864:0
- 26,738 shares0Common StockSEC:0001213900-22-052329:0
- 15,000 shares@ US$0.825100.0% of flowCommon StockSEC:0001213900-22-027501:0Canonical exit: 14 Aug 2022 (T+90)
10 of 10 declarations
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for kidney diseases. It is listed on NASDAQ under the ticker symbol UNCY.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
